Human study for investigating the effects of chronic intake of Ecklonia cava on body fat level and related metabolism in obese adults

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0001074

Enrollment

Registered

2014-04-16

Start date

2014-04-18

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Consumption of placebo or Ecklonia cava for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Subject who voluntarily agree to participate and signs informed consent form 2) 20 years= Age <50 years 3) 25kg/m2= BMI =30kg/m2 4) 1mg/L= blood CRP =10mg/L 5) Skeletal muscle index =39.8% (male), 34.1% (female) 6) Subject who comply with dietary/exercise guidlines for intervention period

Exclusion criteria

Exclusion criteria: 1) Administration of medicine that affect body weight : appetite suppressants/accelerators, hypotensive agents, contraceptive, steroid drug, TCA drug, postmenopausal hormone medicine, laxatives, antidepressant et al. 2) Participation in commercial obesity program or experience of calorie-restricted theraphy within three months before the first visit 3) Subject who has consumed of dietary supplements for body weight control, probiotics, oriental medicine or has been treated with pharmaceutical drug within one month before the first visit 4) Subject with body weight change more than 3kg within three months before the first visit 5) Subject with surgical experience (esophagogastroplasty, enterectomy, et al.) for weight loss 6) Subject with experience of severe depression (hospital treatment or attempt case) 7) Subject with experience of epilepsy or eating disorder 8) Subject with following diseases: - Hypertension - Diabetes(use of hypoglycemic agent) , fasting blood glucose= 180mg/dl or HbA1c= 8.0 - Liver dysfunction - Renal dysfunction - Hyperthyroidism or hypothyroidism - Malignant tumor, heart diesase, lung diseases, asthma, nerve/mental disorder, stomach and intestines disease, hepatitis, Cushing's disease, tuberculosis 9)Subjects with hypersensitivity to test materials 10) Participation in other human study within one month before the first visit 11) Pregnant or lactating women 12) Any condition that the principal investigator believes may put the subjects at undue risk

Design outcomes

Primary

Measure	Time frame
Maker of fat level and related metabolism	—

Secondary

Measure	Time frame
Maker of safety, etc.	—

Countries

Korea, Republic of

Contacts

Public ContactHyo jin Lee

Ewha Womans University

Outcome results